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Age-related macular degeneration is the leading cause 
of blindness in developed countries.1 Since the mid-
2000s, intraocular injections of agents inhibiting vascu-
lar endothelial growth factor (VEGF) have become the 
mainstay of treatment for neovascular (wet) age-related 
macular degeneration.2–4 Emerging data from national 
registries show that blindness related to age-related 
macular degeneration started to fall when anti-VEGF 
treatment was introduced.5 
However, three key questions remain unanswered 
for physicians, their patients, and policy makers. 
First, what is the most cost-eﬀ ective drug? Two anti-
VEGF agents are available: ranibizumab, which was 
approved by the US Food and Drug Administration, 
and bevacizumab, which is a cancer drug widely used 
oﬀ  label.1 Bevacizumab costs a fraction of ranibizumab, 
and is the main drug used in many non-reimbursed 
settings, such as in US practice.6 A report6 suggested 
that US Medicare could save more than US$1 billion 
within 2 years if bevacizumab replaced ranibizumab. 
Second, how often should injections be given? Initial 
clinical trials3,4 suggested that ranibizumab should be 
given monthly for the best visual outcome. In clinical 
practice, physicians and patients would obviously 
prefer injections with intervals of longer than 1 month, 
and alternative regimens (eg, as needed) have been 
proposed. However, whether such alternative regimens 
have acceptable results is unclear. Third, does long-
term treatment have safety issues? Although anti-
VEGF agents are injected in small quantities into the 
eye, concerns about systemic safety have been raised, 
including possible risk of stroke.7,8
In The Lancet, Usha Chakravarthy and colleagues report 
2-year ﬁ ndings of the IVAN randomised controlled trial.9 
This trial, along with the US CATT trial,10,11 attempts to 
answer these questions. In IVAN, adults with untreated 
neovascular age-related macular degeneration were 
randomly assigned to receive intravitreal injections of 
ranibizumab or bevacizumab in continuous (monthly) 
or discontinuous (as needed) regimens.12 Unfortunately, 
the results have not clariﬁ ed the situation. For best 
corrected distance visual acuity—the primary outcome—
bevacizumab was neither non-inferior nor inferior to 
ranibizumab (mean diﬀ erence –1·37 letters in favour of 
ranibizumab, 95% CI –3·75 to 1·01; prespeciﬁ ed non-
inferiority limit 3·5 letters).9 Similarly, discontinuous 
treatment was neither non-inferior nor inferior to con-
tinuous treatment (–1·63 letters in favour of continuous 
treatment, –4·01 to 0·75).9 Can the three questions now 
be answered? 
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savings.10 At my own centre, the percentage of antibiotic 
recipients who develop CDD is right at this boundary, and 
so any shift in eﬀ ect size could tip decision preferences.
PLACIDE is a large and rigorous negative study, and we 
must judge whether it can tip the balance of probiotic 
evidence. Similarly, lactobacilli and biﬁ dobacteria are 
only two types of non-pathogenic bacteria, and we 
must consider whether they can really tip the balance of 
a diverse gut ecosystem.11
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Can the cheaper drug (bevacizumab) achieve results 
that are similar to those of the approved treatment 
(ranibizumab)? Chakravarthy and colleagues9 suggest 
the answer is yes. Although the 2-year IVAN results 
were inconclusive, the meta-analysis of pooled IVAN 
and CATT data9 suggests the diﬀ erence in mean visual 
acuity between drugs is only –1·15 letters in favour of 
ranibizumab (95% CI –2·82 to 0·51). 
Can injections be given less frequently than every 
month and yet achieve similar outcomes? The answer is 
possibly not. CATT showed that the as-needed dosing 
regimen saved nine injections in 2 years, but resulted in 
a small but signiﬁ cant reduction in vision (–2·4 letters) 
compared with monthly treatment.11 Chakravarthy and 
colleagues’ meta-analysis conﬁ rmed that injections given 
as needed led to a small loss of eﬃ  cacy (–2·23 letters, –3·93 
to –0·53).9 Importantly, patients in both trials assigned 
to discontinuous treatment still attended monthly 
monitoring visits, which is often not the case in practice. 
Therefore, although these studies had reasonable results 
with injections given as needed, monthly physician visits 
and monitoring were still necessary, and actual clinical 
outcomes seem to be progressively worse as monthly 
monitoring and treatment are lost.13,14
Finally, are there systemic safety concerns? The answer is 
unclear. Age-related macular degeneration has long been 
suggested to have similar developmental characteristics 
to cardiovascular diseases, and studies15,16 have shown that 
patients with age-related macular degeneration have an 
increased risk of stroke. An observational study based on 
US Medicare7 showed signiﬁ cantly lower risk of all-cause 
mortality, incident myocardial infarction, and stroke with 
ranibizumab than with bevacizumab. In Chakravarthy 
and colleagues’ report,9 no diﬀ erence was recorded in 
frequency of death (odds ratio 0·96, 95% CI 0·46–2·02) 
or of an arterial thrombotic event or hospital admis-
sion for heart failure (1·69, 0·80–3·57) between drugs. 
In CATT, however, more serious adverse events were 
reported in the bevacizumab group than the ranibizumab 
group, although this risk was not dose dependent.10,11 
Intriguingly, systemic safety seemed to be worse when 
treatment was given as needed rather than monthly in 
IVAN: there were fewer deaths (odds ratio 0·47, 0·22-1·03) 
and fewer arterial thrombotic events (0·42, 0·17-1·03) 
with continuous than with discontinuous treatment.9 
This ﬁ nding raises possible new mechanisms of systemic 
interaction— eg, instead of the intuitive dose-dependent 
link, ﬂ uctuation in serum VEGF concentrations might 
be detrimental to systemic vascular health. Another 
explanation that has been suggested is the potential 
protective eﬀ ect of continuous anti-VEGF therapy, 
perhaps by suppressing early malig nancy. Examination 
of serum VEGF concentrations and systemic eﬀ ects in 
oncology patients could be a way to study this association 
further. A limitation of Chakravarthy and colleagues’ 
meta-analysis is that only 1- year data from CATT were 
included for comparison between regimens. Because 
of the small number of events at 1 year (24 deaths and 
27 arterial thrombotic events),10 incorporation of the 
2-year CATT data (68 deaths and 57 arterial thrombotic 
events)11 would be important. 
Thus, the ultimate importance of the IVAN trial 
remains to be established. Despite the similar eﬃ  cacy 
between treatments, the uncertainty about safety 
(particularly systemic events) means ranibizumab users 
are unlikely to switch to bevacizumab and policy makers 
are unlikely to mandate such a switch. A reduction in 
injection frequency also seems to come at the price of a 
proportionate reduction in eﬃ  cacy. 
Chakravarthy and colleagues’ results do not address the 
newest treatment options. Aﬂ ibercept, a VEGF-binding 
fusion protein given every 2 months after loading, was 
approved by the US Food and Drug Administration after 
clinical trials showed its results were non-inferior to those 
of ranibizumab monotherapy.17 Fovista, an aptamer 
against platelet-derived growth factor, has better out-
comes than ranibizumab monotherapy when used in 
combination with ranibizumab.18 With increasingly com-
plex treat ment options, more research will be needed 
to study combination and sequential treatment—used 
widely in oncology. Both the IVAN and CATT studies 
have advanced our understanding of the treatment of 
age-related macular degeneration. Whether these data 
can signiﬁ cantly impact on clinical management and 
eventually lead to adoption of bevacizumab for public 
health funding remains to be seen. The search for a 
cheaper, better, and safer treatment continues. 
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In The Lancet, Sophie Jamal and colleagues1 report an 
updated systematic review and meta-analysis of the 
eﬀ ect on mortality of treatment of chronic kidney disease 
hyperphosphataemia with calcium-based versus non-
calcium-based phosphate binders. Kidneys excrete excess 
dietary phosphate, therefore loss of renal function leads 
to a positive phosphate balance that ultimately results in 
hyperphosphataemia. Excess phosphate might deposit 
in soft tissues, most notably the cardiovascular system, 
as calcium phosphate salts. Observational studies have 
linked high serum phosphate concentrations with adverse 
outcomes in patients with chronic kidney disease and, 
more recently, the general population.2 The phosphate 
removal capacity of dialysis is limited. Thus, chronic 
kidney disease clinical practice guidelines suggest dietary 
restriction of phosphate and use of phosphate binders to 
treat hyperphosphataemia.3
In the late 1980s, calcium-based phosphate binders 
were the treatment of choice for hyperphosphataemia 
associated with chronic kidney disease. Calcium-
based binders had allowed aluminium-based binders 
to be phased out, a full decade after aluminium was 
linked to dialysis encephalopathy.4 A mean dose of 
8·5 g (range 2·5–17) per day of calcium carbonate 
had been reported to control hyperphosphataemia in 
patients on dialysis,5 which implied a mean of 3·4 g per 
day supplemental elemental calcium (up to a maximum 
of 6·8 g per day), well above the 2011 Institute of 
Medicine tolerable upper intake of 2·0 g per day for 
adults older than 50 years. To put this in perspective, the 
recommended daily calcium dietary allowance is 0·8–1·2 g 
for adults, and the tolerable upper intake of calcium was 
lowered in 2011. Emerging evidence suggests that 
calcium supplementation can have potential adverse 
cardiovascular eﬀ ects in the general population.6
Kidney failure also impairs the capacity to excrete excess 
calcium. Calcium from binders is absorbed, as shown 
by increased urinary calcium excretion.7 The problem 
might be compounded by absorption of alkali present 
in calcium-based binders and by concomitant use 
of vitamin D for secondary hyperparathyroidism. 
The concomitant supply of alkali and calcium is the basis 
The demise of calcium-based phosphate binders
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